Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to equity ratio high or low?
The debt to equity ratio of 0.18 is 61% above its 5-year average of 0.11, around the middle of its 5-year range (-3.59–8.59).
As of the fiscal period ended Wednesday, December 31, 2025. 117.03% above its 12-month average of -1.07.
Reported quarterly debt to equity ratio; no daily interpolation. Q4 FY2025 (2025-12-31): 0.18.
DEBT TO EQUITY RATIO
0.18
DEBT TO EQUITY RATIO AVG TTM
-1.07
DEBT TO EQUITY RATIO AVG 3Y
-0.26
DEBT TO EQUITY RATIO AVG 5Y
0.11
DEBT TO EQUITY RATIO AVG 10Y
N/A
DEBT TO EQUITY RATIO AVG 15Y
N/A
DEBT TO EQUITY RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
+117.03%
CURRENT VS 3Y AVG
+170.14%
CURRENT VS 5Y AVG
+61.47%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.11
median of 774 covered companies
CURRENT VS SECTOR MEDIAN
+66.03%
vs the sector median at left
NewGenIvf Group Limited
Market Cap
$6235.00
Debt to Equity Ratio
0.18
TTM Avg
-1.07
3Y Avg
-0.26
5Y Avg
0.11
Market Cap
$30054.00
Debt to Equity Ratio
0.01
TTM Avg
0.11
3Y Avg
0.08
5Y Avg
0.08
Market Cap
$71053.00
Debt to Equity Ratio
0.00
TTM Avg
0.01
3Y Avg
0.01
5Y Avg
0.01
Market Cap
$95475.00
Debt to Equity Ratio
0.00
TTM Avg
0.00
3Y Avg
0.00
5Y Avg
0.00
Market Cap
$106970.00
Debt to Equity Ratio
32.05
TTM Avg
0.18
3Y Avg
0.18
5Y Avg
0.06
Market Cap
$378849.00
Debt to Equity Ratio
0.05
TTM Avg
0.06
3Y Avg
0.04
5Y Avg
0.04
| NAME | MARKET CAP | DEBT TO EQUITY RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| NewGenIvf Group Limited (NIVF) | $6235.00 | 0.18 | -1.07 | -0.26 | 0.11 |
| Mobile-health Network Solutions Class A Ordinary Shares (MNDR)vs › | $30054.00 | 0.01 | 0.11 | 0.08 | 0.08 |
| Zhongchao Inc. (ZCMD)vs › | $30389.00 | 0.00 | 0.00 | 0.03 | 0.02 |
| Akanda Corp. (AKAN)vs › | $61172.00 | N/A | 0.08 | 0.11 | 0.11 |
| PRF Technologies Ltd. (PRFX)vs › | $71053.00 | 0.00 | 0.01 | 0.01 | 0.01 |
| Psyence Biomedical Ltd. (PBM)vs › | $95475.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Silexion Therapeutics Ltd. (SLXN)vs › | $106970.00 | 32.05 | 0.18 | 0.18 | 0.06 |
| SciSparc Ltd. (SPRC)vs › | $252756.00 | 0.09 | 0.05 | 0.03 | 0.08 |
| Virax Biolabs Group Limited (VRAX)vs › | $378849.00 | 0.05 | 0.06 | 0.04 | 0.04 |
| Niki BioSolutions, Inc. (NIKI)vs › | $385197.00 | 0.15 | 0.15 | 0.22 | 0.16 |
Debt/Equity
0.18
Current Ratio
3.12
Debt to Equity measures financial leverage by comparing total debt to shareholders' equity.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO EQUITY RATIO |
|---|---|
| 2025-12-31 | 0.18 |
| 2025-09-30 | 0.19 |
| 2024-12-31 | -3.59 |
| 2024-09-30 | -0.80 |
| 2023-12-31 | 0.09 |
| 2023-09-30 | 0.04 |
| 2023-06-30 | 0.74 |
| 2023-03-31 | 0.00 |
| 2022-12-31 | 0.80 |
| 2022-09-30 | 0.00 |
| 2022-06-30 | 0.00 |
| 2022-03-31 | 0.00 |
| 2021-09-30 | 8.59 |
| 2021-05-31 | 4.47 |
